未切除的局部晚期胰腺癌诱导化疗后立体定向放射治疗与生存率的关系。

IF 0.3 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of Radiotherapy in Practice Pub Date : 2022-09-01 Epub Date: 2021-04-14 DOI:10.1017/s1460396921000212

Sung Jun Ma, Lucas M Serra, Austin J Bartl, Hye Ri Han, Fatemeh Fekrmandi, Austin J Iovoli, Kavitha M Prezzano, Gregory M Hermann, Han Yu, Anurag K Singh

{"title":"未切除的局部晚期胰腺癌诱导化疗后立体定向放射治疗与生存率的关系。","authors":"Sung Jun Ma, Lucas M Serra, Austin J Bartl, Hye Ri Han, Fatemeh Fekrmandi, Austin J Iovoli, Kavitha M Prezzano, Gregory M Hermann, Han Yu, Anurag K Singh","doi":"10.1017/s1460396921000212","DOIUrl":null,"url":null,"abstract":"Background: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the survival benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT) following iC remains unclear.Methods: The National Cancer Database (NCDB) was queried for primary stage III, cT4N0-1M0 LAPC (2004-2015). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used.Results: Among 872 patients, 738 patients underwent CFRT and 134 patients received SBRT. Median follow-up was 24.3 months and 22.9 months for the CFRT and SBRT cohorts, respectively. The use of SBRT showed improved survival in both the multivariate analysis (HR 0.78, p=0.025) and 120 propensity-matched pairs (median OS 18.1 vs 15.9 months, p=0.004) compared to the CFRT.Conclusion: This NCDB analysis suggests survival benefit with the use of SBRT versus CFRT following iC for the LAPC.","PeriodicalId":44597,"journal":{"name":"Journal of Radiotherapy in Practice","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/s1460396921000212","citationCount":"2","resultStr":"{\"title\":\"Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.\",\"authors\":\"Sung Jun Ma, Lucas M Serra, Austin J Bartl, Hye Ri Han, Fatemeh Fekrmandi, Austin J Iovoli, Kavitha M Prezzano, Gregory M Hermann, Han Yu, Anurag K Singh\",\"doi\":\"10.1017/s1460396921000212\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the survival benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT) following iC remains unclear.Methods: The National Cancer Database (NCDB) was queried for primary stage III, cT4N0-1M0 LAPC (2004-2015). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used.Results: Among 872 patients, 738 patients underwent CFRT and 134 patients received SBRT. Median follow-up was 24.3 months and 22.9 months for the CFRT and SBRT cohorts, respectively. The use of SBRT showed improved survival in both the multivariate analysis (HR 0.78, p=0.025) and 120 propensity-matched pairs (median OS 18.1 vs 15.9 months, p=0.004) compared to the CFRT.Conclusion: This NCDB analysis suggests survival benefit with the use of SBRT versus CFRT following iC for the LAPC.\",\"PeriodicalId\":44597,\"journal\":{\"name\":\"Journal of Radiotherapy in Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1017/s1460396921000212\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Radiotherapy in Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/s1460396921000212\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/4/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radiotherapy in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/s1460396921000212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 2

摘要

背景:诱导化疗(iC)后同步放化疗已被证明可提高局部晚期胰腺癌(LAPC)的总生存期(OS)。然而，立体定向放射治疗(SBRT)与传统分次放射治疗(CFRT)在iC后的生存益处尚不清楚。方法:查询国家癌症数据库(NCDB)的原发性III期cT4N0-1M0 LAPC(2004-2015)。采用Kaplan-Meier分析、Cox比例风险法和倾向评分匹配。结果:872例患者中，738例接受了CFRT, 134例接受了SBRT。CFRT和SBRT组的中位随访时间分别为24.3个月和22.9个月。与CFRT相比，SBRT的使用在多变量分析(HR 0.78, p=0.025)和120对倾向匹配对(中位OS 18.1 vs 15.9个月，p=0.004)中均显示生存率提高。结论:这项NCDB分析表明，与CFRT相比，使用SBRT治疗LAPC的生存率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.

Background: Induction chemotherapy (iC) followed by concurrent chemoradiation has been shown to improve overall survival (OS) for locally advanced pancreatic cancer (LAPC). However, the survival benefit of stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation therapy (CFRT) following iC remains unclear.

Methods: The National Cancer Database (NCDB) was queried for primary stage III, cT4N0-1M0 LAPC (2004-2015). Kaplan-Meier analysis, Cox proportional hazards method, and propensity score matching were used.

Results: Among 872 patients, 738 patients underwent CFRT and 134 patients received SBRT. Median follow-up was 24.3 months and 22.9 months for the CFRT and SBRT cohorts, respectively. The use of SBRT showed improved survival in both the multivariate analysis (HR 0.78, p=0.025) and 120 propensity-matched pairs (median OS 18.1 vs 15.9 months, p=0.004) compared to the CFRT.

Conclusion: This NCDB analysis suggests survival benefit with the use of SBRT versus CFRT following iC for the LAPC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Radiotherapy in Practice RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Journal of Radiotherapy in Practice is a peer-reviewed journal covering all of the current modalities specific to clinical oncology and radiotherapy. The journal aims to publish research from a wide range of styles and encourage debate and the exchange of information and opinion from within the field of radiotherapy practice and clinical oncology. The journal also aims to encourage technical evaluations and case studies as well as equipment reviews that will be of interest to an international radiotherapy audience.